Evaluation of GLP-1 Receptor Agonists for Treating Type 2 Diabetes in Adults Tracking Safety, Effectiveness, and Patient Outcomes in Real-World Use

What this Trial Is About

Researchers are evaluating the effects of glucagon-like peptide-1 receptor agonists GLP-1RAs for treating adults with type 2 diabetes mellitus T2DM. The study aims to identify the most effective GLP-1RA drugs and assess their performance across six areas safety, effectiveness, cost, innovation, appropriateness, and accessibility. The goal is to support medical institutions in safely and rationally using these drugs while reducing risks for patients. This observational study involves patients treated with liraglutide, dulaglutide, polyethylene glycol losenatide, or semaglutide. Researchers collect detailed patient information, including demographics, lifestyle habits, hospitalization details, diabetic complications, and medication use during hospital stays. Follow-ups occur at the end of the 4th, 8th, 12th, and 16th weeks of treatment via telephone to track medication adherence, effectiveness, safety, and any adverse reactions. Participants provide data on weight, blood sugar control including HbA1c, lipid levels, kidney and liver function, blood and urine tests, and thyroid function at admission and discharge. Medication use and adverse drug reactions are carefully recorded and assessed. The main outcomes measured are weight reduction and HbA1c compliance at multiple time points, along with safety, medication adherence, changes in lipid levels, blood sugar fluctuations, adverse reactions, and treatment costs over 12 weeks.

Comprehensive Clinical Evaluation Study of GLP-1RA